Publicaciones en colaboración con investigadores/as de Universidad Autónoma de Madrid (32)

2022

  1. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Biomolecules, Vol. 12, Núm. 9

2021

  1. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2015

  1. Endocannabinoids and amyotrophic lateral sclerosis

    Cannabinoids in Neurologic and Mental Disease (Elsevier Inc.), pp. 99-123

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  2. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling

    Journal of Biological Chemistry, Vol. 289, Núm. 32, pp. 21960-21972

2013

  1. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy

    Journal of Alzheimer's Disease, Vol. 35, Núm. 3, pp. 525-539

2012

  1. Cannabinoids: Novel medicines for the treatment of Huntington's disease

    Recent Patents on CNS Drug Discovery, Vol. 7, Núm. 1, pp. 41-48

2011

  1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

  2. Pharmacological targeting of the transcription factor NRf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism

    Antioxidants and Redox Signaling, Vol. 14, Núm. 12, pp. 2347-2360

2009

  1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    GLIA, Vol. 57, Núm. 11, pp. 1154-1167

  2. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas

    Drug and Alcohol Dependence, Vol. 99, Núm. 1-3, pp. 354-358

2008

  1. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats

    Neuropharmacology, Vol. 54, Núm. 6, pp. 976-988

  2. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance

    Neuroscience, Vol. 153, Núm. 3, pp. 687-699

  3. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats

    Neuroscience Letters, Vol. 438, Núm. 1, pp. 10-13

  4. Role of CB2 receptors in neuroprotective effects of cannabinoids

    Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2 SUPPL. 1

2006

  1. Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB1 receptors

    European Journal of Neuroscience, Vol. 24, Núm. 12, pp. 3489-3495

  2. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice

    European Journal of Neuroscience, Vol. 24, Núm. 7, pp. 1874-1884

2004

  1. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

    Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159

2003

  1. Effects of perinatal exposure to Δ9-tetrahydrocannabinol on operant morphine-reinforced behavior

    Pharmacology Biochemistry and Behavior, Vol. 75, Núm. 3, pp. 577-584

2002

  1. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity

    Journal of Neurochemistry, Vol. 82, Núm. 1, pp. 154-158